Literature DB >> 26622765

Acute promyelocytic leukemia harbouring rare FLT3-TKD and WT1 mutations: A case report.

Ting-Ting Liu1, K E Zeng2, Lin Wang3, Ting Liu2, Ting Niu2.   

Abstract

The involvement of the central nervous system (CNS) is rare in acute promyelocytic leukemia (APL). The present study reported the case of a 34-year-old male patient with APL that possessed a rare point mutation (p.Asn841Gly, c.2523C>A) in the tyrosine kinase domain of the FMS-like tyrosine kinase 3 (FLT3) gene and a novel Wilm tumor gene mutation (c.1209_1210insT/p.K404X). The patient suffered central nervous system and systemic relapses twice during systemic and intrathecal chemotherapy. At present, the patient is undergoing alternative induction and consolidation therapies, including the administration of FLT3 inhibitor, tetraarsenic tetrasulfide and novel cytotherapy, and is prepared for salvage allogeneic hematopoietic stem cell transplantion (allo-HSCT). The present study indicated that patients with APL that are at a high risk of relapse and unfavorable gene mutations should receive immediate allo-HSCT, whenever possible.

Entities:  

Keywords:  FLT3-TKD mutation; WT1 mutation; acute promyelocytic leukemia; central nervous system relapse; multiple relapses; prognosis

Year:  2015        PMID: 26622765      PMCID: PMC4533715          DOI: 10.3892/ol.2015.3437

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  22 in total

1.  FLT3 internal tandem duplication is associated with a high relapse rate and central nervous system involvement in acute promyelocytic leukemia cases: single institutional analysis.

Authors:  Haruko Tashiro; Ryosuke Shirasaki; Yoko Oka; Toshihiko Sugao; Mitsuho Mizutani-Noguchi; Tadashi Yamamoto; Nobu Akiyama; Kazuo Kawasugi; Naoki Shirafuji
Journal:  Eur J Haematol       Date:  2011-01-11       Impact factor: 2.997

2.  Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients.

Authors:  Ulrike Bacher; Claudia Haferlach; Wolfgang Kern; Torsten Haferlach; Susanne Schnittger
Journal:  Blood       Date:  2007-10-26       Impact factor: 22.113

3.  WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system.

Authors:  Hsin-An Hou; Tai-Chung Huang; Liang-In Lin; Chieh-Yu Liu; Chien-Yuan Chen; Wen-Chien Chou; Jih-Luh Tang; Mei-Hsuan Tseng; Chi-Fei Huang; Ying-Chieh Chiang; Fen-Yu Lee; Ming-Chih Liu; Ming Yao; Shang-Yi Huang; Bor-Sheng Ko; Szu-Chun Hsu; Shang-Ju Wu; Woei Tsay; Yao-Chang Chen; Hwei-Fang Tien
Journal:  Blood       Date:  2010-04-05       Impact factor: 22.113

4.  Extramedullary relapse after all-trans retinoic acid treatment in acute promyelocytic leukemia--the occurrence of retinoic acid syndrome is a risk factor.

Authors:  B S Ko; J L Tang; Y C Chen; M Yao; C H Wang; M C Shen; H F Tien
Journal:  Leukemia       Date:  1999-09       Impact factor: 11.528

5.  Internal tandem duplication and Asp835 mutations of the FMS-like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemia.

Authors:  Lee-Yung Shih; Ming-Chung Kuo; Der-Cherng Liang; Chein-Fuang Huang; Tung-Liang Lin; Jin-Hou Wu; Po-Nan Wang; Po Dunn; Chang-Liang Lai
Journal:  Cancer       Date:  2003-09-15       Impact factor: 6.860

6.  Extramedullary involvement at relapse in acute promyelocytic leukemia patients treated or not with all-trans retinoic acid: a report by the Gruppo Italiano Malattie Ematologiche dell'Adulto.

Authors:  G Specchia; F Lo Coco; M Vignetti; G Avvisati; P Fazi; F Albano; F Di Raimondo; B Martino; F Ferrara; C Selleri; V Liso; F Mandelli
Journal:  J Clin Oncol       Date:  2001-10-15       Impact factor: 44.544

7.  Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia.

Authors:  Rosemary E Gale; Robert Hills; Arnold R Pizzey; Panagiotis D Kottaridis; David Swirsky; Amanda F Gilkes; Elizabeth Nugent; Kenneth I Mills; Keith Wheatley; Ellen Solomon; Alan K Burnett; David C Linch; David Grimwade
Journal:  Blood       Date:  2005-08-16       Impact factor: 22.113

8.  Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis.

Authors:  Pau Montesinos; Joaquín Díaz-Mediavilla; Guillermo Debén; Virginia Prates; Mar Tormo; Vicente Rubio; Inmaculada Pérez; Isolda Fernández; Maricruz Viguria; Chelo Rayón; José González; Javier de la Serna; Jordi Esteve; Juan M Bergua; Concha Rivas; Marcos González; Jose D González; Silvia Negri; Salut Brunet; Bob Lowenberg; Miguel A Sanz
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941

Review 9.  Acute promyelocytic leukemia: from highly fatal to highly curable.

Authors:  Zhen-Yi Wang; Zhu Chen
Journal:  Blood       Date:  2008-03-01       Impact factor: 22.113

Review 10.  Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate.

Authors:  R Ohno; N Asou; K Ohnishi
Journal:  Leukemia       Date:  2003-08       Impact factor: 11.528

View more
  1 in total

1.  Evolution of a FLT3-TKD mutated subclone at meningeal relapse in acute promyelocytic leukemia.

Authors:  Tilmann Bochtler; Stefan Fröhling; Wilko Weichert; Volker Endris; Christian Thiede; Barbara Hutter; Michael Hundemer; Anthony D Ho; Alwin Krämer
Journal:  Cold Spring Harb Mol Case Stud       Date:  2016-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.